Oncolys Biopharma Inc.
Overview
Oncolys BioPharma Inc. is a Tokyo-based biotechnology company established in March 2004, focusing on the development of innovative treatments for cancer and serious infectious diseases using virology-based drug discovery technologies. Their lead product, Telomelysin (OBP-301), is an oncolytic adenovirus immunotherapy currently in clinical development targeting various solid tumors.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Oncolys Biopharma Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.